文献速递胸部肿瘤泌尿男性生殖肿瘤

在高级别肺与前列腺神经内分泌肿瘤患者中使用[89Zr]Zr-DFO-SC16.56抗DLL3抗体成像:一项1/2期首次人体试验

Imaging with [89Zr]Zr-DFO-SC16.56 anti-DLL3 antibody in patients with high-grade neuroendocrine tumours of the lung and prostate: a phase 1/2, first-in-human trial.
PubMed 文献 · Lancet Oncol · 2024-06-28

这项首次人体1/2期试验在Memorial Sloan Kettering癌症中心开展,评估了DLL3靶向示踪剂[89Zr]Zr-DFO-SC16.56在神经内分泌来源癌症患者中的安全性和可行性。研究纳入18例患者,结果显示成像安全可行,肿瘤摄取与DLL3免疫组化表达一致。

要点

  • 在18例患者中,1例(6%)出现1级过敏反应,未观察到2级或更严重不良事件。
  • 队列2中,15例患者中12例(80%)的DLL3亲和肿瘤可通过单次免疫PET-CT delineate。
  • 肿瘤摄取与DLL3免疫组化在16例可评估组织患者中15例(94%)一致。

核心结论

  • DLL3 PET-CT成像在神经内分泌癌症患者中是安全可行的,这些结果显示了[89Zr]Zr-DFO-SC16.56用于无创体内检测表达DLL3的恶性肿瘤的潜在效用。

研究设计与样本

  • 开放标签、首次人体1/2期研究,在美国纽约州纽约市Memorial Sloan Kettering癌症中心进行。
  • 纳入年龄≥18岁、组织学证实为神经内分泌来源恶性肿瘤且ECOG体能状态评分为0-2的患者。
  • 队列1(SCLC患者)接受37-74 MBq [89Zr]Zr-DFO-SC16.56单次静脉输注,总质量剂量2.5 mg,并在注射后1小时、第1天、第3天和第7天进行系列PET-CT扫描。
  • 队列2(扩展队列,包括SCLC、神经内分泌前列腺癌、非典型类癌肿瘤和非小细胞肺癌患者)接受相同活性和质量剂量的单次输注,并在3-6天后进行单次PET-CT扫描。
  • 回顾性收集的肿瘤活检样本通过免疫组化评估DLL3。

主要发现

  • 2020年2月11日至2023年1月30日期间,共入组18例患者(12例[67%]男性,6例[33%]女性),中位年龄64岁(范围23-81)。
  • 队列1包括3例患者,队列2包括15例额外患者。
  • 队列1中3例SCLC患者在注射后第3天和第7天显示强烈的肿瘤特异性[89Zr]Zr-DFO-SC16.56摄取。
  • 血清清除呈双相,估计终末清除半衰期为119小时(SD 31)。
  • 最高平均吸收剂量在肝脏(1.83 mGy/MBq [SD 0.36]),平均有效剂量为0.49 mSv/MBq(SD 0.10)。

关键数值与推荐

  • 队列1给予37-74 MBq [89Zr]Zr-DFO-SC16.56,总质量剂量2.5 mg。
  • 队列2给予与初始队列相同的活性和质量剂量。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Delta-like ligand 3 (DLL3) is aberrantly expressed on the surface of small-cell lung cancer (SCLC) and neuroendocrine prostate cancer cells. We assessed the safety and feasibility of the DLL3-targeted imaging tracer [89Zr]Zr-DFO-SC16.56 (composed of the anti-DLL3 antibody SC16.56 conjugated to p-SCN-Bn-deferoxamine [DFO] serving as a chelator for zirconium-89) in patients with neuroendocrine-derived cancer. METHODS: We conducted an open-label, first-in-human study of immunoPET-CT imaging with [89Zr]Zr-DFO-SC16.56. The study was done at Memorial Sloan Kettering Cancer Center, New York, NY, USA. Patients aged 18 years or older with a histologically verified neuroendocrine-derived malignancy and an Eastern Cooperative Oncology Group performance status of 0-2 were eligible. An initial cohort of patients with SCLC (cohort 1) received 37-74 MBq [89Zr]Zr-DFO-SC16.56 as a single intravenous infusion at a total mass dose of 2·5 mg and had serial PET-CT scans at 1 h, day 1, day 3, and day 7 post-injection. The primary outcomes of phase 1 of the study (cohort 1) were to estimate terminal clearance half-time, determine whole organ time-integrated activity coefficients, and assess the safety of [89Zr]Zr-DFO-SC16.56. An expansion cohort of additional patients (with SCLC, neuroendocrine prostate cancer, atypical carcinoid tumours, and non-small-cell lung cancer; cohort 2) received a single infusion of [89Zr]Zr-DFO-SC16.56 at the same activity and mass dose as in the initial cohort followed by a single PET-CT scan 3-6 days later. Retrospectively collected tumour biopsy samples were assessed for DLL3 by immunohistochemistry. The primary outcome of phase 2 of the study in cohort 2 was to determine the potential association between tumour uptake of the tracer and intratumoural DLL3 protein expression, as determined by immunohistochemistry. This study is ongoing and is registered with ClinicalTrials.gov, NCT04199741. FINDINGS: Between Feb 11, 2020, and Jan 30, 2023, 12 (67%) men and six (33%) women were enrolled, with a median age of 64 years (range 23-81). Cohort 1 included three patients and cohort 2 included 15 additional patients. Imaging of the three patients with SCLC in cohort 1 showed strong tumour-specific uptake of [89Zr]Zr-DFO-SC16.56 at day 3 and day 7 post-injection. Serum clearance was biphasic with an estimated terminal clearance half-time of 119 h (SD 31). The highest mean absorbed dose was observed in the liver (1·83 mGy/MBq [SD 0·36]), and the mean effective dose was 0·49 mSv/MBq (SD 0·10). In cohort 2, a single immunoPET-CT scan on day 3-6 post-administration could delineate DLL3-avid tumours in 12 (80%) of 15 patients. Tumoural uptake varied between and within patients, and across anatomical sites, with a wide range in maximum standardised uptake value (from 3·3 to 66·7). Tumour uptake by [89Zr]Zr-DFO-SC16.56 was congruent with DLL3 immunohistochemistry in 15 (94%) of 16 patients with evaluable tissue. Two patients with non-avid DLL3 SCLC and neuroendocrine prostate cancer by PET scan showed the lowest DLL3 expression by tumour immunohistochemistry. One (6%) of 18 patients had a grade 1 allergic reaction; no grade 2 or worse adverse events were noted in either cohort. INTERPRETATION: DLL3 PET-CT imaging of patients with neuroendocrine cancers is safe and feasible. These results show the potential utility of [89Zr]Zr-DFO-SC16.56 for non-invasive in-vivo detection of DLL3-expressing malignancies. FUNDING: National Institutes of Health, Prostate Cancer Foundation, and Scannell Foundation.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Tendler S, Dunphy MP, Agee M, et al. Imaging with [89Zr]Zr-DFO-SC16.56 anti-DLL3 antibody in patients with high-grade neuroendocrine tumours of the lung and prostate: a phase 1/2, first-in-human trial. Lancet Oncol. 2024. PMID: 38950555. doi:10.1016/S1470-2045(24)00249-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。